A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Cancer Cell

Volumn 8, Issue 5, 2005, Pages 407-419

  Chauhan, Dharminder ^a   Catley, Laurence ^a   Li, Guilan ^a   Podar, Klaus ^a   Hideshima, Teru ^a   Velankar, Mugdha ^a   Mitsiades, Constantine ^a   Mitsiades, Nicolas ^a   Yasui, Hiroshi ^a   Letai, Anthony ^a   Ovaa, Huib ^a   Berkers, Celia ^a   Nicholson, Benjamin ^b   Chao, Ta Hsiang ^b   Neuteboom, Saskia T C ^b   Richardson, Paul ^a   Palladino, Michael A ^b   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LACTACYSTIN BETA LACTONE; MELPHALAN; NPI 0052; PROTEASOME INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LINE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR MODEL; TUMOR RECURRENCE;

ANIMALIA;

EID: 27644562277     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.10.013     Document Type: Article

References (39)

1. J. Adams Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer Curr. Opin. Chem. Biol. 6 2002 493 500
2. J. Adams The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 4 2004 349 360
3. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 59 1999 2615 2622
4. K.C. Anderson Bortezomib therapy for myeloma Curr. Hematol. Rep. 3 2004 65
5. C.R. Berkers, M. Verdoes, E. Lichtman, E. Fiebiger, B.M. Kessler, K.C. Anderson, H.L. Ploegh, H. Ovaa, and P.J. Galardy Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib Nat. Methods 2 2005 357 362
6. M. Bogyo, S. Shin, J.S. McMaster, and H.L. Ploegh Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes Chem. Biol. 5 1998 307 320
7. E. Bossy-Wetzel, and D.R. Green Apoptosis: checkpoint at the mitochondrial frontier Mutat. Res. 434 1999 243 251
8. D. Chauhan, and K.C. Anderson Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications Apoptosis 8 2003 337 343
9. D. Chauhan, P. Pandey, A. Ogata, G. Teoh, N. Krett, R. Halgren, S. Rosen, D. Kufe, S. Kharbanda, and K.C. Anderson Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells J. Biol. Chem. 272 1997 29995 29997
10. D. Chauhan, T. Hideshima, S. Rosen, J.C. Reed, S. Kharbanda, and K.C. Anderson Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells J. Biol. Chem. 276 2001 24453 24456
11. D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, N. Munshi, S. Kharbanda, and K.C. Anderson JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells J. Biol. Chem. 278 2003 17593 17596
12. D. Chauhan, T. Hideshima, and K.C. Anderson Proteasome inhibition in multiple myeloma: therapeutic implication Annu. Rev. Pharmacol. Toxicol. 45 2005 465 476
13. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
14. E.J. Corey, and W.D. Li Total synthesis and biological activity of lactacystin, omuralide and analogs Chem. Pharm. Bull. (Tokyo) 47 1999 1 10
15. B. Guo, D. Zhai, E. Cabezas, K. Welsh, S. Nouraini, A.C. Satterthwait, and J.C. Reed Humanin peptide suppresses apoptosis by interfering with Bax activation Nature 423 2003 456 461
16. T. Hideshima, and K.C. Anderson Molecular mechanisms of novel therapeutic approaches for multiple myeloma Nat. Rev. Cancer 2 2002 927 937
17. T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dong, A. Castro, and V. Palombella NF-κB as a therapeutic target in multiple myeloma J. Biol. Chem. 277 2002 16639 16647
18. B.M. Kessler, D. Tortorella, M. Altun, A.F. Kisselev, E. Fiebiger, B.G. Hekking, H.L. Ploegh, and H.S. Overkleeft Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits Chem. Biol. 8 2001 913 929
19. T.H. Landowski, C.J. Megli, K.D. Nullmeyer, R.M. Lynch, and R.T. Dorr Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines Cancer Res. 65 2005 3828 3836
20. L.M. Lashinger, K. Zhu, S.A. Williams, M. Shrader, C.P. Dinney, and D.J. McConkey Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells Cancer Res. 65 2005 4902 4908
21. R. LeBlanc, L.P. Catley, T. Hideshima, S. Lentzsch, C.S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C.S. Pien, and J. Adams Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Res. 62 2002 4996 5000
22. E.S. Lightcap, T.A. McCormack, C.S. Pien, V. Chau, J. Adams, and P.J. Elliott Proteasome inhibition measurements: clinical application Clin. Chem. 46 2000 673 683
23. V.R. Macherla, S.S. Mitchell, R.R. Manam, K.A. Reed, T.H. Chao, B. Nicholson, G. Deyanat-Yazdi, B. Mai, P.R. Jensen, and W.F. Fenical Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor J. Med. Chem. 48 2005 3684 3687
24. L.K. Miller An exegesis of IAPs: salvation and surprises from BIR motifs Trends Cell Biol. 9 1999 323 328
25. C.S. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S.P. Treon, N.C. Munshi, P.G. Richardson, and K.C. Anderson Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications Oncogene 21 2002 5673 5683
26. N. Mitsiades, C.S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T.A. Libermann, and S.P. Treon Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc. Natl. Acad. Sci. USA 99 2002 14374 14379
27. E.A. Obeng, and L.H. Boise Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis J. Biol. Chem. 280 2005 29578 29587
28. V.J. Palombella, E.M. Conner, J.W. Fuseler, A. Destree, J.M. Davis, F.S. Laroux, R.E. Wolf, J. Huang, S. Brand, and P.J. Elliott Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis Proc. Natl. Acad. Sci. USA 95 1998 15671 15676
29. K. Podar, Y.T. Tai, B.K. Lin, R.P. Narsimhan, M. Sattler, T. Kijima, R. Salgia, D. Gupta, D. Chauhan, and K.C. Anderson Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα activation J. Biol. Chem. 277 2002 7875 7881
30. J.C. Rathmell, and C.B. Thompson Pathways of apoptosis in lymphocyte development, homeostasis, and disease Cell Suppl. 109 2002 S97 S107
31. P.G. Richardson A review of the proteasome inhibitor bortezomib in multiple myeloma Expert Opin. Pharmacother. 5 2004 1321 1331
32. P.G. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, and H. Goldschmidt Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 352 2005 2487 2498
33. S.M. Russo, J.E. Tepper, A.S. Baldwin Jr., R. Liu, J. Adams, P. Elliott, and J.C. Cusack Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB Int. J. Radiat. Oncol. Biol. Phys. 50 2001 183 193
34. A. Strasser, L. O'Connor, and V.M. Dixit Apoptosis signaling Annu. Rev. Biochem. 69 2000 217 245
35. B.A. Teicher, G. Ara, R. Herbst, V.J. Palombella, and J. Adams The proteasome inhibitor PS-341 in cancer therapy Clin. Cancer Res. 5 1999 2638 2645
36. M.C. Wei, W.X. Zong, E.H. Cheng, T. Lindsten, V. Panoutsakopoulou, A.J. Ross, K.A. Roth, G.R. MacGregor, C.B. Thompson, and S.J. Korsmeyer Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 292 2001 727 730
37. S. Willis, C.L. Day, M.G. Hinds, and D.C. Huang The Bcl-2-regulated apoptotic pathway J. Cell Sci. 116 2003 4053 4056
38. F. Xu, A. Gardner, Y. Tu, P. Michl, D. Prager, and A. Lichtenstein Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors Br. J. Haematol. 97 1997 429 440
39. W.X. Zong, C. Li, G. Hatzivassiliou, T. Lindsten, Q.C. Yu, J. Yuan, and C.B. Thompson Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis J. Cell Biol. 162 2003 59 69